Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002;92(1):183-191.
Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 2010;57(1):90-100.
The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011;30:13.
Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57(7):1276-1280.
Immunity, inflammation, and cancer. Cell 2010;140(6):883-899.
The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-788.
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(17):5930-5939.
COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92(7):1888-1895.
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1(5):339-348.
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095-2101.
Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106(2):129-134.
Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23(10):1269-1278.
From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res 2004;64(12):4309-4318.
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7(5):R 796-807.
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11(17):6261-6269.
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4(9):1448-1455.
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study. Cancer Prev Res (Phila) 2014 Mar;7(3):283-291.
CTGF inhibits cell motility and COX-2 expression in oral cancer cells. Int Immunopharmacol 2011;11(8):948-954.
MAP kinases: charting the regulatory pathways. Science 1992;257(5075):1355-1356.
Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006;25(4):763-773.
Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin Chim Acta 2012;413(1):219-225.
Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase. Biochim Biophys Acta 2013;1830(3):2763-2769.
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8(4):945-954.
The STATs of cancer.new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013;4(3):176-185.
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol 2014 Oct;50(10):930-941.
Guggulsterone inhibits NF-kappa B and Ikappa Balpha kinase activation, suppresses expression of antiapoptotic gene products, and enhances apoptosis. J Biol Chem 2004;279(45):47148-47158.
Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005;4(11):1747-1754.
Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005;4(12):1982-1992.
Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol 2007;74(1):118-130.
Guggulsteroneinduced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007;67(15):7439-7449.
Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009;279(1):93-100.
Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008;68(11):4406-4415.
Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30(11):1848-1856.
Guggulsterone (GS) inhibits smokeless tobacco and nicotineinduced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 2011;32(3):368-380.
Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells. PLoS One 2011;6(2):e14728.
ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002;4(6):408-415.
RhoC GT Pase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60(20):5832-5838.
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004;6(1):R110-115.
Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(3):295-302.
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2(5):418-425.
RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006;12(15):4485-4490.
Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013;49(8):778-786.
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2(10):941-948.
Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARgamma. Biochim Biophys Acta 2012;1822(7):1090-1095.
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10:365-376.
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12(3):181-195.
Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008;73(3):709-717.
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003;94(4):365-371.
Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007;25(18 Suppl):1511.
Pioglitazone and risk of bladder cancer among diabetic patients in France: a opulation based cohort study. Diabetologia 2012;55(7):1953-1962.
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents—implications for drug interactions. Br J Clin Pharmacol 1995;40(6):523-530.
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acutephase response. Br J Cancer 2002;87(3):277-280.
Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-232.
Interleukin 1β inhibits CAR induced expression of hepatic genes involved in drug and bilurubin clearance. Hepatology 2004;40(4):951-960.
Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 2002;181-182:207-210.
Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274(3):707-713.